These findings collectively confirm that CDC7 is a crucial downstream effector of PLK1 for cell survival upon oxaliplatin treatment and that targeting the PLK1‐MYC‐CDC7 axis can enhance oxaliplatin‐based chemotherapy regimens in CRC. This evidence concerns the gene MYC and colorectal carcinoma.